PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12207141::ACT019622

LCKLSL

Evidence text

Paper-level observation

Figure 5I: All of them [matrine, PY60, and hexapeptide] increased the HSP90-immunoprecipitated TAP1 contents.
figureConfidence: medium

Assay observation

Activity
Immunomodulatory
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
increased
Normalized measurement
=0
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Huh-7
Assay method
Not reported by source
Sequence
LCKLSL
Standardization
ready simple

Source publication

Targeting Annexin A2 to reactivate tumor-associated antigens presentation and relieve immune tolerance in liver cancer.

Journal for Immunotherapy of Cancer · 2025

DOI 10.1136/jitc-2025-011716 PMC12207141
Parent mention

Related peptide identities

PEPDIA-PLP-001707

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.